Case-control study of statin prevention of mould infections

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Thompson, Jessica N ^a   Huycke, Mark M ^a   Greenfield, Ronald A ^a   Kurdgelashvili, George ^a   Gentry, Chris A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Invasive mould infections; Prophylaxis; Statin

Indexed keywords

CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ARTICLE; ASPERGILLOSIS; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IN VITRO STUDY; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MOULD; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; ZYGOMYCOSIS;

ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; CHEMOPREVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; UNITED STATES;

ASPERGILLUS; HUMAN IMMUNODEFICIENCY VIRUS; ZYGOMYCETES;

EID: 80052810557     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01957.x     Document Type: Article

References (14)

1. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Mycology 2001; 41: 211-4.
2. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
3. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-60.
4. Konotoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007; 44: 1089-90.
5. Roze LV, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998; 25: 119-33.
6. Lukacs G, Papp T, Nyilasi I et al. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004; 42: 5400-2.
7. Chamilos G, Lewis RE, Kontoyiannis K. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50: 96-103.
8. Galgoczy L, Papp T, Lukacs G et al. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 2007; 270: 109-15.
9. Qiao J, Kontoyiannis DP, Wan Z et al. Antifungal activity of statins against Aspergillus species. Med Mycol 2007; 45: 589-93.
10. Macreadie IG, Johnson G, Schlosser T et al. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006; 262: 9-13.
11. Natesan SK, Chandrasekar PH, Alangaden GJ et al. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 2008; 60: 369-73.
12. Galgoczy L, Papp T, Vagvolgyi C. In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses 2008; 52: 447-53.
13. Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol 2010; 59: 200-5.
14. Galgoczy L, Nyilasi I, Papp T, Vagvolgyi C. Are statins applicable for the prevention and treatment of zygomycosis? Clin Infect Dis 2009; 49: 483-4.